Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) 373% HIGHER; announced positive results from the Phase 3 trial of VYXEOS (cytarabine: daunorubicin) Liposome ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

Jefferies Cuts Price Target on Immunomedics (IMMU) as Clivatuzumab Program is Discontinued March 15, 2016 8:15 AM Wedbush Reiterates Outperform as Outerwall (OUTR) Looks to Maximize Value March 15, 2016 7:59 AM Piper Jaffray Remains Sidelined as Cost Cuts Drive ITT Educational Services' (ESI) EPS Beat March 15, 2016 7:42 AM Needham & Company Raises Price Target on Inogen (INGN) to $47 Following Strong 4Q Beat and Raise March 15, 2016 6:47 AM